Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Wright Reports
|
$449.00
|
|
Provider: GlobalData
|
$125.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
TAIKO PHARMACEUTICAL CO LTD Issues Consolidated Mid-year Forecast for FY 2012
TAIKO PHARMACEUTICAL CO LTD announced that it has issued the consolidated mid-year forecast for revenue of JPY 3,019 million, operating profit of JPY 547 million, ordinary profit of JPY 546 million, net profit of JPY 405 million and earning per share of JPY 31.33 for the fiscal year ending March 2012.
Latest Developments for Taiko Pharmaceutical Co Ltd
- TAIKO PHARMACEUTICAL CO LTD Raises Full-year Forecast for FY 2013
- TAIKO PHARMACEUTICAL CO LTD Raises Year-end Dividend Forecast for FY 2013
- TAIKO PHARMACEUTICAL CO LTD Raises Consolidated Full-year Outlook for FY 2013
- TAIKO PHARMACEUTICAL CO LTD Raises Consolidated Full-year Outlook and Year-end Dividend Outlook for FY Ended March 2012
Latest Key Developments in Pharmaceuticals
- Sanofi SA and Regeneron Pharmaceuticals Inc Announce Positive Phase 2a Results of Dupilumab in Asthma
- Abbott Laboratories Announces CE Mark For Coronary Drug Eluting Stent
- Medivir AB Announces Positive Results from Phase Ia Study with MIV-711 for Treatment of Skeletal Disorders
- Grifols SA Signs Deal To License Aradigm Corp's Pulmaquin; May Buy 35% Stake In Aradigm Corp-Reuters
- Share this
- Link this
- Digg this
Follow Reuters